BindingDB logo
myBDB logout

44 articles for thisTarget

The following articles (labelled with PubMed ID or TBD) are for your review
PMIDDataArticle TitleOrganization
25654260 49 Discovery of highly selective brain-penetrant vasopressin 1a antagonists for the potential treatment of autism via a chemogenomic and scaffold hopping approach.EBI F. Hoffmann-La Roche Inc
25642985 45 Selective nonpeptidic fluorescent ligands for oxytocin receptor: design, synthesis, and application to time-resolved FRET binding assay.EBI University of Strasburg
24874785 333 New, potent, and selective peptidic oxytocin receptor agonists.EBI Ferring Research Institute Inc.
16250654 41 2,5-diketopiperazines as potent, selective, and orally bioavailable oxytocin antagonists. 2. Synthesis, chirality, and pharmacokinetics.EBI GlaxoSmithKline
21700453 56 Optimisation of pharmacokinetic properties to afford an orally bioavailable and selective V1A receptor antagonist.EBI MSD
21458261 55 The discovery of novel 8-azabicyclo[3.2.1]octan-3-yl)-3-(4-chlorophenyl) propanamides as vasopressin V1A receptor antagonists.EBI MSD
21146408 53 The characterization of a novel V1b antagonist lead series.EBI GlaxoSmithKline
20674355 58 Pyrrolo[1,2-a]pyrazine and pyrazolo[1,5-a]pyrazine: novel, potent, and selective series of Vasopressin 1b receptor antagonists.EBI GlaxoSmithKline
19081251 38 Discovery and optimisation of a potent and selective tertiary sulfonamide oxytocin antagonist.EBI GlaxoSmithKline
22984902 59 Selective fluorescent nonpeptidic antagonists for vasopressin V2 GPCR: application to ligand screening and oligomerization assays.EBI University of Strasburg
22239250 59 Pyridyl-2,5-diketopiperazines as potent, selective, and orally bioavailable oxytocin antagonists: synthesis, pharmacokinetics, and in vivo potency.EBI GlaxoSmithKline
22425346 28 Synthesis and evaluation of C-11, F-18 and I-125 small molecule radioligands for detecting oxytocin receptors.EBI Emory University
19800231 92 Tetrahydroquinoline sulfonamides as vasopressin 1b receptor antagonists.EBI Schering-Plough Research Institute
18032036 17 The discovery of GSK221149A: a potent and selective oxytocin antagonist.EBI GlaxoSmithKline
17850055 18 Toward efficient drug screening by homogeneous assays based on the development of new fluorescent vasopressin and oxytocin receptor ligands.EBI Institute Genomics Functional (IGF)
16302826 129 Discovery and development of a new class of potent, selective, orally active oxytocin receptor antagonists.EBI Serono Pharmaceutical Research Institute
15084136 96 Design of potent and selective agonists for the human vasopressin V1b receptor based on modifications of [deamino-cys1]arginine vasopressin at position 4.EBI Medical College of Ohio
12036367 46 Synthesis and characterization of fluorescent antagonists and agonists for human oxytocin and vasopressin V(1)(a) receptors.EBI University of Montpellier
22249122 9 Synthesis and evaluation of potent and selective human V1a receptor antagonists as potential ligands for PET or SPECT imaging.EBI Lehigh University
21688787 295 New, potent, selective, and short-acting peptidic V1a receptor agonists.EBI Ferring Research Institute Inc.
21605973 69 Potent and selective oxindole-based vasopressin 1b receptor antagonists with improved pharmacokinetic properties.EBI Abbott Laboratories
21601454 26 Identification and optimisation of novel sulfonamide, selective vasopressin V1B receptor antagonists.EBI MSD
21596563 33 Synthesis and SAR studies of novel 2-(6-aminomethylaryl-2-aryl-4-oxo-quinazolin-3(4H)-yl)acetamide vasopressin V1b receptor antagonists.EBI MSD
21428295 43 Design, synthesis, and pharmacological characterization of fluorescent peptides for imaging human V1b vasopressin or oxytocin receptors.EBI University of Montpellier
21353540 55 Synthesis and SAR studies of novel 2-(4-oxo-2-aryl-quinazolin-3(4H)-yl)acetamide vasopressin V1b receptor antagonists.EBI MSD
20550119 96 Oral oxytocin antagonists.EBI DrugMolDesign
20719508 26 Identification and optimization of novel 2-(4-oxo-2-aryl-quinazolin-3(4H)-yl)acetamide vasopressin V3 (V1b) receptor antagonists.EBI Ligand Pharmaceuticals Inc
18778939 23 Triazole oxytocin antagonists: identification of aryl ether replacements for a biaryl substituent.EBI Pfizer Inc
10197974 22 Fluorescent pseudo-peptide linear vasopressin antagonists: design, synthesis, and applications.EBI University of Montpellier
30098866 30 Novel, potent, selective and brain penetrant vasopressin 1b receptor antagonists.EBI AbbVie Deutschland GmbH & Co. KG
30199637 172 LIT-001, the First Nonpeptide Oxytocin Receptor Agonist that Improves Social Interaction in a Mouse Model of Autism.EBI UMR7200 CNRS/Universit£ de Strasbourg
29602673 49 Building bridges for highly selective, potent and stable oxytocin and vasopressin analogs.EBI Imperial College
26469307 7 Phosphorylation of Capsaicinoid Derivatives Provides Highly Potent and Selective Inhibitors of the Transcription Factor STAT5b.BDB University of Leipzig
16302795 36 Lysosomotropism of basic cathepsin K inhibitors contributes to increased cellular potencies against off-target cathepsins and reduced functional selectivity.BDB Merck Frosst Centre for Therapeutic Research
1874734 53 The bisindolylmaleimide GF 109203X is a potent and selective inhibitor of protein kinase C.BDB Laboratoires Glaxo
9216835 30 Potent HIV protease inhibitors containing a novel (hydroxyethyl)amide isostere.BDB Boehringer Ingelheim (Canada) Ltd